GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV)
shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a
history of GUD and are HSV-2 seropositive and HIV-1 seronegative randomized in a 2:1 ratio to
receive episodic acyclovir 400mg orally three times daily or matching placebo three times
daily for 5 days and who are followed for a total of 13 days.
Phase:
N/A
Details
Lead Sponsor:
University of Washington
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)